Market News
Dyne Therapeutics (DYN), a clinical-stage company dedicated to improving the lives of individuals with genetically driven neuromuscular diseases, has announced the pricing of an upsized public offering of 18,980,478 shares of its common stock at a price of $18.44 per share. The offering is expected to generate gross proceeds of approximately $350 million before deducting underwriting discounts and commissions.
The offering, which is solely comprised of shares sold by Dyne, is anticipated to close around December 11, 2025, subject to customary closing conditions. Additionally, Dyne has granted underwriters a 30-day option to purchase up to 2,847,071 additional shares at the public offering price, minus the underwriting fees.
Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are serving as joint book-running managers for this public offering.
This offering is made under a shelf registration statement on Form S-3 that Dyne filed with the Securities and Exchange Commission (SEC) on March 5, 2024, which became effective automatically. Investors can access the preliminary prospectus supplement detailing the terms of the offering on the SEC’s website at www.sec.gov. Once available, the final prospectus supplement and the accompanying prospectus can also be obtained from the underwriters.
Dyne Therapeutics specializes in developing therapeutics aimed at addressing the root causes of neuromuscular diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company is focused on providing functional improvements for affected individuals and communities.
This announcement includes forward-looking statements that involve risks and uncertainties. Actual outcomes may differ significantly from those anticipated due to various factors, including the satisfaction of customary closing conditions for the public offering.
For more information about Dyne Therapeutics and its offerings, visit insideticker.com/ticker/DYN.